NCT00724425 2015-04-15
A Phase 1 Dose Escalation Study of IPI-493
Infinity Pharmaceuticals, Inc.
Phase 1 Terminated
Clinical Trials
6 trialsNCT01193491 2015-04-15
Dose Escalation of IPI-493 in Hematologic Malignancies
Infinity Pharmaceuticals, Inc.
Phase 1 Terminated
NCT00688766 2012-12-11
Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib
Infinity Pharmaceuticals, Inc.
Phase 3 Terminated
NCT00817362 2012-12-11
Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
Infinity Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00627419 2012-12-10
A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma
Infinity Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00319930 2010-03-08
Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL
Biogen
Phase 1 Terminated